SCHEMBL4906889

SCHEMBL4906889

CC(C)c1cc(Nc2c(N[C@H](C)c3cccc(O)c3)c(=O)c2=O)ccc1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 17/20 0.65
AURKB Q96GD4 4/20 0.46
MAPK1 P28482 4/20 0.46
ROCK1 Q13464 3/20 0.46
CYP2C9 P11712 3/20 0.46
PDGFRA P16234 3/20 0.46
CSNK1G1 Q9HCP0 3/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
RPS6KA1 Q15418 2/20 0.46
DCLK1 O15075 1/20 0.46
ROCK2 O75116 1/20 0.46
CHEK2 O96017 1/20 0.46
GSK3A P49840 1/20 0.46
GSK3B P49841 1/20 0.46
IRAK1 P51617 1/20 0.46
PRKX P51817 1/20 0.46
NEK4 P51957 1/20 0.46
PLK1 P53350 1/20 0.46
CSNK1G2 P78368 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4916307 0.88 MAPKAPK2 (0.54) MAPKAPK2AURKBMAPK1ROCK1CYP2C9
SCHEMBL4914542 0.88 MAPKAPK2 (0.59) MAPKAPK2AURKBMAPK1ROCK1CYP2C9
SCHEMBL1228998 0.87 MAPKAPK2 (0.67) MAPKAPK2AURKBMAPK1ROCK1CYP2C9
SCHEMBL4911215 0.87 MAPKAPK2 (0.67) MAPKAPK2AURKBMAPK1ROCK1CYP2C9
SCHEMBL4914345 0.87 MAPKAPK2 (0.67) MAPKAPK2AURKBMAPK1ROCK1CYP2C9
SCHEMBL4915655 0.85 MAPKAPK2 (0.64) MAPKAPK2AURKBMAPK1ROCK1CYP2C9
SCHEMBL4916066 0.84 MAPKAPK2 (0.63) MAPKAPK2AURKBMAPK1ROCK1CYP2C9
SCHEMBL4914122 0.84 MAPKAPK2 (0.63) MAPKAPK2AURKBMAPK1ROCK1CYP2C9
SCHEMBL4916032 0.83 MAPKAPK2 (0.61) MAPKAPK2AURKBMAPK1ROCK1CYP2C9
SCHEMBL4911119 0.82 MAPKAPK2 (0.60) MAPKAPK2AURKBMAPK1ROCK1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080262096-A1 Squaric Acid Derivatives MERCK PATENT GMBH (DE) 2008-10-23 US claimed
EP-1838662-A1 SQUARIC ACID DERIVATIVES Merck Patent GmbH (DE) 2007-10-03 EP claimed
WO-2006072354-A1 SQUARIC ACID DERIVATIVES MERCK PATENT GMBH (DE) 2006-07-13 WO claimed
US-20080262096-A1 Squaric Acid Derivatives MERCK PATENT GMBH (DE) 2008-10-23 US disclosed
EP-1838662-A1 SQUARIC ACID DERIVATIVES Merck Patent GmbH (DE) 2007-10-03 EP disclosed
WO-2006072354-A1 SQUARIC ACID DERIVATIVES MERCK PATENT GMBH (DE) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262096-A1 Squaric Acid Derivatives GLS, SGK1, PFKL MAPKAPK2 1309/4885AURKB 1018/4885MAPK1 1446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.